Hansa Biopharma at a glance

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-degrading enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).

Hansa’s research and development program is advancing the next generation of the Company’s enzyme technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the US.

Our Equity Story

Imlifidase works
Targeting rare diseases with a high unmet medical need
Addresses a clear unmet need
Preparing for commercialization
Well positioned for commercial success
Evolution into a fully integrated biopharmaceutical company
Rich pipeline
Leveraging our proprietary antibody cleaving enzyme technology

Learn More



Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcomming Events

Milestones and near-term news flow

Near Term News Near Term News

For any investor related inquiries, please contact IR@hansabiopharma.com